Clinical assessment and treatment of ADHD in children

International Journal of Clinical Practice

Volumn 61, Issue 10, 2007, Pages 1730-1738

  Smoot, L C ^a   Boothby, L A ^b,d   Gillett, R C ^c  

^a AUBURN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

^c Columbus Regional's Physician Group ^*  (United States)

^d BCPS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXEDRINE SPANSULE; DEXMETHYLPHENIDATE; FOCALIN XR; GUANFACINE; LISDEXAMFETAMINE; METHYLIN ER; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; PEMOLINE; PEMOLINE MAGNESIUM; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; VYVANSE; WELLBUTRIN XR;

ANOREXIA; APPETITE; APPETITE SUPPRESSION; APPLICATION SITE REACTION; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BLOOD PRESSURE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COUGHING; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; HYPERKINESIA; INSOMNIA; IRRITABILITY; LIVER TOXICITY; NARCOLEPSY; NAUSEA; NERVOUSNESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH PAIN; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR THERAPY; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FAMILY THERAPY; FEMALE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 34548618323     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01519.x     Document Type: Review

References (57)

1. Global ADHD Working Group. Global Consensus on ADHD/HKD. Eur Child Adolesc Psychiatry 2005 14 : 127 37.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, DSM-TR-IV®. Washington, DC : American Psychiatric Association, 2000 : 85.
3. WHO. International Classification of Diseases, 10th edn. World Health Organization, 2007. http://www.who.int/classifications/apps/icd/icd10online/ (accessed August 2, 2007).
4. Biederman J, Faraone SV. Attention deficit-hyperactivity disorder. Lancet 2005 366 : 237 48.
5. American Academy of Pediatrics. Committee on Quality Improvement and Subcommittee on Attention-Deficit/Hyperactivity Disorder. Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000 105 : 1158 70.
6. Barkley RA. International Consensus Statement on ADHD. Clin Child Fam Psychol Rev 2002 5 : 89 111.
7. Scottish Intercollegiate Guidelines Network. Attention Deficit and Hyperkinetic Disorders in Children and Young People, 2001. http://www.sign.ac. uk/pdf/sign52.pdf (accessed June 2007).
8. National Institute for Health and Clinical Excellence. Methylphenidate, Atomoxetine and Dexamfetamine for Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents, 2006. http://www.guidance.nice.org.uk/TA9B/ guidance/pdf/English (accessed June 2007).
9. Wilens TE, Dobson W. A clinical perspective of attention-deficit/ hyperactivity disorder into adulthood. J Clin Psychiatry 2004 54 : 1301 13.
10. Rappley MD. Attention deficit-hyperactivity disorder. N Engl J Med 2005 352 : 165 73.
11. Rushton JL, Fant KE, Clark SJ. Use of practice guidelines in the primary care of children with attention-deficit/hyperactivity disorder. Pediatrics 2004 114 : e23 8.
12. Gardner W, Kelleher KJ, Pajer KA, Campo JV. Primary care clinicians' use of standardized psychiatric diagnoses. Child Care Health Dev 2004 30 : 401 12.
13. Pliszka SR, Crismon ML, Hughes CW et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for the pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 45 : 642 57.
14. American Academy of Pediatrics, Committee on Quality Improvement and Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 2001 108 : 1033 44.
15. TM as a Novel Treatment for ADHD. Shire Press Release, 23 February, 2007. http://www.tktx.com (accessed June 2007).
16. Hogan V. Pemoline (Cylert(R)): market withdrawal. Can Med Assoc J 2000a 162 : 106.
17. Medwatch FDA. Alert for Healthcare Professionals: Pemoline Tablets and Chewable Tablets (Marketed as CYLERT). http://www.fda.gov/medwatch/safety/2005/ safety05.htm#Cylert (accessed October 2005).
18. MTA. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder: the multimodal treatment study of children with ADHD. Arch Gen Psychiatry 1999 56 : 1073 86.
19. Pliszka SR, Browne RG, Olvera RL et al. A double-blind, placebo controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2000 39 : 619 26.
20. Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 2002 22 : 468 73.
21. Pelham WE, Aronof HR, Midlam JL et al. A comparison of ritalin and Adderall; efficacy and time course in children with attention hyperactivity deficit disorder. Pediatrics 1999 103 : e43.
22. McCracken JT, Biederman J, Greenhill LL et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLL381 (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychol 2003 426 : 673 83.
23. Biederman J, Lopez FA, Boellner SW et al. A randomized, double blind, placebo controlled parallel group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 2002 110 : 258 66.
24. Efron D, Jarman F, Barker M. Efficacy of methylphenidate and dextroamphetamine in children with attention hyperactivity disorder: a double blind crossover trial. Pediatrics 1997 100 : 662 8.
25. Wolraich ML, Greenhill LL, Pelham W et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 2001 108 : 883 92.
26. Pelham WE, Gnagy EM, Burrows-Maclean L et al. Once-a-day Concerta-methylphenidate versus three times daily methylphenidate in laboratory and natural settings. Pediatrics 2001 107 : 1 15.
27. Lopez F, Silva R, Pestreich L et al. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs 2003 5 : 545 55.
28. Wilens TE, Biederman J, Lerner M, Concerta Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol 2004 24 : 36 41.
29. Greenhill LL, Findling RL, Swanson JM et al. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002 109 : 1 7.
30. Pelham WE, Greenslade KE, Vodde-Hamilton M et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990 86 : 226 37.
31. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006 13 : e50 62.
32. Noven Announces FDA Approval of Daytrana Methylyphenidate Transdermal System. http://www.noven.com/PR040606.htm (accessed January 2007).
33. FDA Psychopharmacologic Drugs Advisory Committee briefing document on Methylphenidate Transdermal System NDA 21-514. Noven Pharmaceuticals, Inc. Shire Development Inc. 2 December, 2005. http://www.fda.gov/ohrms/dockets/ac/05/ briefing/2005-4195B1_01_01-Noven-Briefing-Document.pdf (accessed August 2006).
34. McGough JJ, Wigal SB, Abikoff H, Turnhow JM, Posner K, Moon E. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 2006 9 : 476 85.
35. Greenhill LL, Pliszka S, Dulcan MK et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002 41 : 26S 49.
36. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of Attention-Deficit/Hyperactivity Disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003 111 : 179 85.
37. Spencer TJ, Faraone SV, Biederman J et al. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry 2006 45 : 527 37.
38. Jellin JM Safety concerns of ADHD Drugs - an update. Pharmacist's Lett/Prescriber's Lett 2006 22 : 220505.
39. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006 354 : 1445 8.
40. Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006 21 : 92 5.
41. FDA Briefing Document Regarding Cardiovascular Labeling for ADHD Drugs. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006- 4210b_17_01_CV%20labeling%20list.pdf (accessed January 2007).
42. FDA Asks Attention-Deficit Hyperactivity Disorder (ADHD) Drug Manufacturers to Develop Patient Medication Guides. http://www.fda.gov/cder/ drug/infopage/ADHD/ (accessed February 2007).
43. Cephalon Receives Non-Approvable Letter on SPARLON(TM). http://www.cephalon.com/newsroom/news_reader.aspxzID=894363 (accessed August 2006).
44. Wilens TE, Newcorn JH, Kratochvil CJ et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr 2006 149 : 112 9.
45. Strattera (Package Insert). Indianapolis, IN : Eli Lilly and Company, 2007.
46. Lim JR, Faught PR, Chalasani NP, Molleston JP. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr 2006 148 : 831 4.
47. Stojanovski SD, Casavant MJ, Mousa HM, Baker P, Nahata MC. Atomoxetine-induced hepatitis in a child. Clin Toxicol 2007 45 : 51 5.
48. Kratochvil CJ, Heiligenstein JH, Dittmann R et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002 41 : 776 84.
49. Biederman J, Heiligenstein JH, Faries DE et al., Atomoxetine ADHD Study Group. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics 2002 110 : e75.
50. Michaelson D, Adler L, Spencer T et al. Atomoxetine in the treatment of children and adolescents with attention deficit, hyperactivity disorder: a randomized, placebo controlled, dose response study. Pediatrics 2001 108 : 1 9.
51. Spencer T, Heiligenstein JH, Biederman J et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 63 : 1140 7.
52. Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter randomized prospective study. Adv Ther 2005 22 : 498 512.
53. Wigal SB, McGough JJ, McCracken JT et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit-hyperactivity disorder. J Atten Disord 2005 9 : 275 89.
54. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 2006 16 : 260 72.
55. Turgay A. Treatment of comorbidity in conduct disorder with attention-deficit hyperactivity disorder (ADHD). Essent Psychopharmacol 2005 6 : 277 90.
56. Marcason W. Can Dietary Intervention Play a Part in the Treatment of Attention Deficit and Hyperactivity Disorder? J Am Diet Assoc 2005 105 : 1161 2.
57. Micromedex® Healthcare Series (intranet database). Greenwood Village, CO : Thomson Micromedex, 2007.